How Trig, Inc. Turned a Simple Idea Into a Sales Organization

In 2018, Adrienne P. saw something many people overlooked.

Major national brands were expanding. Retail environments were evolving. Digital marketing was growing fast. Yet many companies still needed something simple and human: real conversations with customers.

That gap in the market led to the launch of Trig, Inc., a Columbus, Ohio–based sales and leadership development organization.

The idea behind the company was direct. Represent brands face-to-face. Build trust with customers. And develop the next generation of business leaders along the way.

“The industry often focuses on quick transactions,” Adrienne says. “But we’ve always believed in real conversations. If you understand the customer, the rest of the process becomes clearer.”

That belief helped shape Trig from its earliest days.

The Story Behind the Name Trig

Unlike many companies, the name Trig does not come from a long business backstory.

Instead, it came from a simple moment of creativity.

“I scrambled the word grit and landed on Trig,” Adrienne says. “There wasn’t some deep branding exercise behind it.”

But the meaning behind the word stuck.

Grit became a quiet theme inside the company. It reflected the work ethic required to succeed in a competitive sales environment.

“Hard work, discipline, and consistency matter more than flashy ideas,” Adrienne says. “That mindset shaped how we built the company.”

The focus was never just growth. It was sustainable growth.

Why Face-to-Face Sales Still Matters

Trig was founded to meet market expansion demand from national clients. Many brands needed strong in-person representation in retail locations, sports venues, and event environments.

While technology continues to change the sales world, Adrienne believes personal interaction still plays an important role.

“People want information, but they also want connection,” Adrienne says. “A conversation allows you to understand what someone actually needs.”

Trig teams represent products and services directly to customers in these environments. The goal is not to rush the interaction.

Instead, the company trains team members to ask questions and listen carefully.

“Our model is simple,” Adrienne explains. “It has to be a win for the client, a win for the customer, and a win for the team. If it’s not all three, we don’t move forward.”

That approach helped the company build long-term relationships with clients rather than relying on short-term results.

Building a Culture Around Leadership and Growth

From the outside, Trig might look like a traditional sales organization. But inside the company, the focus is broader.

Adrienne describes Trig as a leadership and entrepreneurial development organization.

Team members are trained in more than just product knowledge. They learn communication skills, emotional intelligence, leadership habits, and business thinking.

Many employees begin with limited business experience. Over time, they develop the ability to lead teams, manage performance, and solve problems independently.

Adrienne believes this approach benefits both the company and the individuals involved.

Recognizing Consistent Performance Over Time

Since launching in March 2018, Trig has received more than 25 awards tied to performance, leadership, compliance, and customer satisfaction.

Some of the recognitions include:

• Campaign Pacesetter Awards
• National Pacesetter honors
• Market Expansion Leadership Awards
• Consistency Awards
• Million Dollar Club Awards from 2018 through 2025

One achievement stands out in particular.

Trig has earned Campaign Cup recognition for seven consecutive years, recognizing the highest sales production among comparable channels used by its clients.

Adrienne says the recognition reflects long-term consistency rather than one strong year.

“Anyone can have a good season,” she says. “What matters is maintaining that level over time.”

The awards also reinforce the company’s focus on discipline and steady improvement.

The Role of Integrity in High-Performance Work

Sales organizations often face pressure to prioritize numbers.

Adrienne believes strong results matter. But they must be paired with integrity.

“High performance without integrity doesn’t last,” she says. “But integrity without performance is ineffective.”

That balance shapes how Trig approaches customer interactions.

Representatives are trained to understand customer needs before presenting products or services. The company encourages team members to slow down conversations and listen carefully.

“People can tell when you’re just trying to close something,” Adrienne says. “If you focus on understanding first, you build trust.”

That trust often leads to stronger relationships between brands and customers.

The Long-Term Vision for Trig, Inc.

More than seven years after its launch, Trig continues to operate with the same mindset that shaped its founding.

Integrity remains central. Performance is expected. And growth is constant.

Adrienne believes the company’s biggest impact may come from the people it develops along the way.

“We’re building leaders who create opportunity for others,” she says.

That focus on leadership development is what Adrienne sees as the company’s long-term contribution to the industry.

“We build for our clients,” she says. “But we grow as a team.”

For Trig, the formula is straightforward.

Integrity is the foundation. Performance is the standard. And growth is a daily habit driven by grit.

The Federal Aviation Administration lifted ground stops Friday evening at Ronald Reagan Washington National Airport and other major airports serving the Washington, D.C., region after a strong chemical smell at a key air traffic control facility forced a temporary halt to operations.

The disruptions began around 4:50 p.m. when the FAA issued ground stops at Reagan National (DCA), Washington Dulles International (IAD) and Baltimore-Washington International Thurgood Marshall (BWI) airports. The agency cited a “strong chemical smell” at the Potomac Consolidated Terminal Radar Approach Control (TRACON) facility in Warrenton, Virginia, about 50 miles west of the capital, that was impacting some air traffic controllers.

The Potomac TRACON manages approach and departure traffic for the busy airspace covering the D.C. metropolitan area, as well as Richmond International Airport (RIC) in Virginia, which also fell under a ground stop. Additional airports in the facility’s coverage area, including Charlottesville-Albemarle Airport and Manassas Regional Airport, experienced similar restrictions. Philadelphia International Airport (PHL) faced ground delays tied to the regional ripple effects.

FAA officials initially described the issue as an “equipment outage” on their status page, but later clarified in statements that the odor was the primary cause, affecting controller operations. The agency did not immediately identify the source of the smell or confirm whether it posed a health risk, though no injuries or evacuations were reported at the TRACON facility.

Transportation Secretary Sean Duffy addressed the situation on social media, stating that the FAA was actively investigating the odor and working to resolve it. “The FAA is investigating a strong odor coming from Potomac TRACON,” Duffy posted. In follow-up updates, officials emphasized efforts to “address the source of the strong odor.”

By approximately 7:45 p.m., the FAA lifted the full ground stops at DCA, IAD and BWI. Flights resumed under ground delay programs, with some departures facing waits of up to three hours or more into the overnight period Friday into Saturday. Dulles reported departure delays climbing to 90 minutes and increasing during the peak of the disruption.

Passengers at the affected airports reported long lines and uncertainty as airlines scrambled to manage the backlog. At Reagan National, located along the Potomac River just minutes from downtown Washington, travelers posted photos of crowded terminals and gates with delayed or canceled flights. Similar scenes unfolded at Dulles, the region’s main international gateway, and BWI, which serves as a major hub for Southwest Airlines.

The incident highlights the vulnerability of the nation’s air traffic system to even localized issues at control facilities. The Potomac TRACON handles thousands of flights daily in one of the country’s most congested airspaces, where military operations, commercial traffic and presidential movements frequently overlap.

FAA spokesperson Donnell Evans confirmed in an email that the smell directly affected controllers, prompting the precautionary halt to prevent safety risks. “The FAA has temporarily stopped traffic … because of a strong chemical smell at the Potomac TRACON that is impacting some air traffic controllers,” Evans said.

Authorities have not released details on what caused the odor, though some social media speculation from aviation observers suggested possible HVAC issues, maintenance chemicals or an environmental factor at the facility. The FAA said investigations were ongoing, with no immediate indication of foul play or a hazardous materials incident requiring broader emergency response.

As operations normalized, airlines began issuing waivers for rebooking and changes without fees. Travelers were advised to check flight status directly with carriers or through the FAA’s flight status tools.

The ground stop lasted roughly three hours at its peak, a relatively short duration compared to past major disruptions but enough to create cascading delays across the East Coast. By late Friday evening, the focus shifted to recovery, with controllers reportedly back online after the facility addressed the immediate concerns.

The FAA urged passengers to monitor fly.faa.gov for real-time updates. No further ground stops were anticipated as of late Friday, though residual delays were expected to persist into Saturday morning.

This incident marks another reminder of how sensitive the aviation network is to issues beyond weather or mechanical problems at individual airports. Officials have not indicated any long-term impact on operations.

By Jennifer Nash

U.S. economic growth cooled more than expected in Q4 2025, according to the BEA’s latest estimate. Real GDP rose at just a 0.7% annual rate, falling well short of the 1.4% forecast and marking a steep drop-off

EXCLUSIVE: The White House is expecting to announce an expansion of drugmakers offering discounts on TrumpRx.gov, FOX Business has learned.

As early as today, Amgen and GSK will be added to the list of prescription drug manufacturers offering discounts on the government website. That makes a total of 54 prescription medications from six pharmaceutical companies that have signed on to the most-favored-nation pricing under pressure from President Donald Trump and the threat of tariffs.

Amgen will offer medication on the website that cuts 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis.

FOX NEWS POLL: VOTERS SOUND ALARM ON HEALTHCARE COSTS

President Donald Trump speaks as Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz looks on during an event on drug pricing in the South Court Auditorium on the White House campus Feb. 5, 2026, in Washington, D.C. (Nathan Howard/Getty Images)

The company plans to list Aimovig and Repatha for discounts of 62%.

GSK will discount Incruse at 55% of the retail price. The drug treats COPD and will be listed at $159.

GSK also plans to list Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%.

“GSK and Amgen connecting with TrumpRx.gov to offer prescription drugs directly to consumers at most-favored-nations pricing marks another milestone for President Trump’s affordability push,” White House spokesman Kush Desai told FOX Business. 

“TrumpRx.gov is just the beginning, however, as Americans are set to (receive) even greater drug pricing discounts, lower insurance premiums and more transparency when Congress passes President Trump’s Great Healthcare Plan.”

Amgen will offer medication on the website that cuts 80% off the retail price. (George Frey/Bloomberg via Getty Images)

The Pharmaceutical Research and Manufacturers of America represents major drug companies.

CEO Stephen Ubl believes “Government-imposed most-favored-nation policies would undermine U.S. competitiveness while doing nothing to address insurance practices that deny care and raise costs for patients.

HOUSE GOP SEEKS OFF-RAMP TO SKY-HIGH HEALTH INSURANCE COSTS FOR MILLIONS OF AMERICANS

“These policies would siphon billions from American R&D, slow the pace of cures and increase reliance on China for future innovation.”

GSK will discount Incruse at 55% of the retail price. (Jeffrey Greenberg/Universal Images Group via Getty Images)

The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Operator

Greetings, and welcome to Vaxart’s Stockholder Fireside Chat Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the webcast over to David Carey, Finn Partners.

David Carey
Finn Partners, Inc.

Good afternoon, and welcome to today’s call. Joining us from Vaxart are Steve Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James S. Cummings, Chief Medical Officer; Jeroen Grasman, Chief Financial Officer; and Ed Berg, Senior Vice President and General Counsel.

Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company’s financial results, financial guidance, its future business strategies and operations, any partnerships with third parties, timing of any anticipated regulatory approvals or that any such approval will be obtained, the company’s future cash runway, ability to regain compliance with NASDAQ listing standards or raise capital if such listing is regained, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could materially differ from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the Risk Factors section of Vaxart’s most recently filed annual report on Form 10-K and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update